Aidoc
Clinical AI platform for radiology and enterprise imaging workflows.
Last updated: June 5, 2026
Back to directoryKheiron's Mia platform supports breast-screening workflows, including Mia Triage for double-reader triage and Mia IQ for image-quality assurance.
Screening programs evaluating AI as a governed support layer for double-reading capacity, quality assurance, and pathway efficiency.
Compare within workflow: Medical imaging and radiology · comparison shortlist · source index
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Kheiron Mia as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Review each module separately because Mia Triage, Mia Reader, Mia IQ, and RSViP may have different intended uses and country-specific authorization paths. |
|---|---|
| Privacy | Assess mammography image flow, patient identifiers, PACS/RIS integration, cloud or distributor processing, retention, access controls, audit logs, and data-processing terms. |
| Evidence | Require local screening-program evidence for detection, recall, workload, image quality, population fit, scanner mix, and post-market monitoring rather than relying only on headline performance claims. |
| Workflow | Best governed as pathway support for radiologist-reviewed screening, with explicit rules for triage thresholds, quality-audit actions, second-reader escalation, and patient-safety review. |
Kheiron describes Mia as a breast screening AI platform with Mia Triage for double-reading triage and Mia IQ for image-quality assurance; product pages state CE/UK status for Mia, TGA and Medsafe clearance for Mia, and FDA registration for Mia IQ in the United States.
Not for: U.S. diagnostic mammography claims without product-specific FDA review, autonomous recall decisions, or assuming Mia Triage and Mia IQ have identical regulatory status.
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.